On Thursday, Shares of Citigroup Inc (NYSE:C), subtract -0.47% and closed at $48.47 in the last trading session. The last trading range of the stock ranges between $47.54 and $48.68. Citi has rebranded the Liquifi ATS into CitiBLOC, an alternative trading system designed for block execution. The platform leverages conditional orders to seek block execution while minimizing the opportunity cost typically associated with trading blocks of stocks. It is designed to only accept auto firm-ups, and has a nearly 90% normalized firm-up rate.1
CitiBLOC accepts conditional buy and sell orders and sends an invitation to firm-up to each of the participants when there is a potential match. It has an exclusive rank, time matching priority. Rank is determined by a combination of firm-up rate and size of firm-up orders. A minimum size of 5,000 shares or a notional value of at least US$100,000 is required per order. The crossing engine is also compliant with the SEC’s tick size pilot as all executions are done at midpoint.
“CitiBLOC is designed to leverage the conditional order concept in very unique and innovative ways seamlessly finding block crossing opportunities while encouraging and rewarding the right behavior among clients,” said John Procopion, Head of CitiBLOC. “We have created a closed-end venue that will assist streamline the process and establish a safe and secure trading environment.”
Baxter International Inc (NYSE:BAX), jumped 1.58% and closed at $47.72 in the last trading session. The last trading range of the stock ranges between $46.64 and $47.89. The company’s Market capitalization is $25.94 Billion with the total outstanding Shares of 543.89 million. Baxter International Inc. (BAX), a global leader in PN therapy, partnered with the American Society for Parenteral and Enteral Nutrition (ASPEN) and the Agency for Healthcare Research and Quality (AHRQ) to co-author a new statistical brief – ”Characteristics of Hospital Stays Involving Malnutrition, 2013” – about the often overlooked consequences of disease-related malnutrition.
The new statistical data characterizes the impact of malnutrition in U.S. hospitalized patients in human and economic costs – concluding malnutrition is associated with up to five times higher risk of in-hospital deaths, may result in two times longer hospital stays, and creates an estimated $42 billion1 burden to the healthcare system.
”I believe the fundamental reason malnutrition is underdiagnosed and undertreated is that we lack objective, measurable means to diagnose the condition,” said Paul Wischmeyer, M.D., E.D.I.C., Department of Anesthesiology and Duke Clinical Research Institute, Duke University Medical Center. ”I teach that nutrition assessment has to occur in every patient, and at-risk patients should be started on thoughtful nutrition therapy within 48 hours.”
Myriad Genetics, Inc. (NASDAQ:MYGN), dropped -3.07% and closed at $18.62 in the last trading session. The last trading range of the stock ranges between $17.66 and $18.87. During the 52-week trading session the minimum price at which share price traded, registered at $17.66 and reached to max level of $46.24. Myriad Genetics, Inc. (MYGN), a leader in molecular diagnostics and personalized medicine, recently declared that its myChoice® HRD test identified more than double the number of patients who may benefit from treatment with niraparib than were identified by germline BRCA testing alone. The myChoice HRD test was evaluated in the NOVA study (NCT01847274) of nirarapib, an investigational oral PARP inhibitor being developed by TESARO (TSRO).
Recently`s declarement follows publication of the NOVA study in the New England Journal of Medicine. NOVA is a well-controlled Phase 3 trial of niraparib that enrolled 553 patients with recurrent ovarian cancer who responded to their most recent platinum-based chemotherapy. This trial was designed to assess progression free survival (PFS) in a broad population of patients who were assigned to one of two cohorts based upon germline BRCA mutation status.